OncoMatch/Clinical Trials/NCT05870423
Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
Is NCT05870423 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies olaparib for neuroendocrine tumors.
Treatment: olaparib — This is a phase 1 dose-escalation study to determine the maximum tolerated dose of the PARP inhibitor olaparib in combination with PRRT in patients with a well-differentiated advanced gastroenteropancreatic NET (GEP NET), progressive after PRRT. As secondary objectives, efficacy, pharmacokinetics and biomarker response will be investigated.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Neuroendocrine Tumor
Disease stage
Grade: 123
Prior therapy
Must have received: peptide receptor radionuclide therapy (177Lu-DOTATATE) — initial or salvage
Disease progression based on RECIST v1.1 following initial or salvage treatment with PRRT with 177Lu-DOTATATE
Cannot have received: surgery
Exception: within 12 weeks prior to inclusion
Any surgery...within 12 weeks prior to inclusion in the study.
Cannot have received: radioembolization
Exception: within 12 weeks prior to inclusion
radioembolization...within 12 weeks prior to inclusion in the study.
Cannot have received: chemoembolization
Exception: within 12 weeks prior to inclusion
chemoembolization...within 12 weeks prior to inclusion in the study.
Cannot have received: chemotherapy
Exception: within 12 weeks prior to inclusion
chemotherapy...within 12 weeks prior to inclusion in the study.
Cannot have received: radiofrequency ablation
Exception: within 12 weeks prior to inclusion
radiofrequency ablation within 12 weeks prior to inclusion in the study.
Cannot have received: interferon (interferons)
Exception: within 4 weeks prior to inclusion
Interferons...within 4 weeks prior to inclusion in the study.
Cannot have received: mTOR inhibitor (everolimus)
Exception: within 4 weeks prior to inclusion
everolimus...within 4 weeks prior to inclusion in the study.
Cannot have received: VEGFR inhibitor (sunitinib)
Exception: within 4 weeks prior to inclusion
sunitinib...within 4 weeks prior to inclusion in the study.
Cannot have received: systemic therapy
Exception: within 4 weeks prior to inclusion
other systemic therapies within 4 weeks prior to inclusion in the study.
Cannot have received: external beam radiation therapy
Exception: to more than 25% of the bone marrow
Prior external beam radiation therapy to more than 25% of the bone marrow.
Lab requirements
Blood counts
Hb concentration <6.2 mmol/L; white blood cell count <3x10^9/L; platelets <100x10^9/L; neutrophil count <1.5x10^9/L
Kidney function
creatinine clearance <50 mL/min, measured in 24-hour urine collection
Liver function
total bilirubin >3 x ULN, ALT or AST > 2.5 x ULN or serum albumin <3.0 g/dL unless prothrombin time is within the normal range
Cardiac function
Uncontrolled congestive heart failure (NYHA II, III, IV) [excluded]
Hb concentration <6.2 mmol/L; white blood cell count <3x10^9/L; platelets <100x10^9/L; neutrophil count <1.5x10^9/L. Renal insufficiency defined as a creatinine clearance <50 mL/min, measured in 24-hour urine collection. Liver function or enzyme abnormalities defined as a total bilirubin >3 x ULN, Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULN or serum albumin <3.0 g/dL unless prothrombin time is within the normal range. Uncontrolled congestive heart failure (NYHA II, III, IV) [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05870423 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior surgery, radioembolization, chemoembolization disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages